Facebook Facebook Share

As part of our policy and campaigns work Target Ovarian Cancer regularly produces reports which cover issues including awareness of the symptoms of ovarian cancer and women’s experience of treatment.

We also respond to consultations from public bodies, including the government, the NHS, and bodies responsible for clinical guidelines in relation to ovarian cancer or access to new drugs and treatments. When a public body plans to change an existing, or introduce a new, policy or set of guidelines, then it runs a public consultation. Our responses reflect the priorities of women with ovarian cancer and the changes needed to improve diagnosis and treatment.

Reports

The Ovarian Cancer Postcode lotteryThe Ovarian Cancer Postcode lottery

While cancer doesn’t discriminate according to postcode, Target Ovarian Cancer research has found that women’s awareness of the symptoms, access to clinical trials and likelihood of surviving ovarian cancer can vary hugely according to where they live.

Read the report

Pathfinder 2016Pathfinder 2016

Pathfinder is Target Ovarian Cancer’s groundbreaking research that provides a detailed picture of the experiences of people living and working with ovarian cancer in the UK.

Read the report

Consultation responses

Proposed changes to how the National Institute for Health and Care Excellence (NICE) evaluates and funds new drugs - October 2016 – January 2017

NHS England and NICE consulted on changes to how new drugs are evaluated and funded, including a proposal for a further process for any new drug expected to cost the NHS £20 million a year or more.

Read the consultation document

Proposals for changes to how NICE evaluates and funds new drugs

Read our response

Proposals for changes to NICE evaluations - a response from Target Ovarian Cancer - January 2017

Proposed changes to Clinical Reference Groups (CRGs) - February 2016 – March 2016

CRGs are responsible for setting the standards to which services for more specialised care, including for ovarian cancer, are commissioned. This consultation looked at how they are structured.

Read the consultation document

Proposed revisions to Clinical Reference Groups

Read our response

Proposed revisions to Clinical Reference Groups - a response from Target Ovarian Cancer - March 2016

Changes to the Cancer Drugs Fund - November 2015 – February 2016

NHS England and National Institute for Health and Care Excellence consultation on changes to the Cancer Drugs Fund.

Read the consultation document

Consultation on proposals for a new Cancer Drugs Fund

Read our response

Consultation on proposals for a new Cancer Drugs Fund - a response from Target Ovarian Cancer - February 2016

Genetic testing for BRCA1 and BRCA2 mutations - March 2015 – April 2015

Following new guidelines in 2013 which recommended that all women with non-mucinous ovarian cancer be offered genetic, NHS England consulted on how this should be commissioned.

Read the consultation document

Clinical Commissioning Policy on genetic testing for BRCA1 and BRCA2 mutations

Read our response

Draft Clinical Commissioning Policy - genetic testing for BRCA1 and BRCA2 mutations - a response from Target Ovarian Cancer - April 2015

Call for evidence for new cancer strategy for England - November 2014 – February 2015

The Government asked Sir Harpal Kumar, Chief Executive of Cancer Research UK, to lead an independent taskforce to develop a new five year cancer strategy for England.

Read our response

Cancer strategy taskforce - a response from Target Ovarian Cancer - February 2015